Global Lenacapavir Market Research Report 2026

Lenacapavir Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Lenacapavir competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Lenacapavir is a long-acting HIV-1 capsid inhibitor that exerts its antiviral effect by specifically binding to the viral capsid protein, thereby blocking the assembly, release, and uncoating processes of HIV and ultimately inhibiting viral replication. Characterized by its novel mechanism of action, prolonged half-life, and reduced dosing frequency, it is indicated both for the treatment of adults with multidrug-resistant HIV-1 infection and as a long-acting agent for pre-exposure prophylaxis (PrEP). By offering a novel option for the treatment and prevention of HIV/AIDS, it is particularly beneficial for patients with suboptimal responses to conventional regimens or those with poor medication adherence.In 2025, global Lenacapavir production reached approximately 450,000 vials (注射液) and 300,000 bottles（片剂）

Lenacapavir is the world’s first long-acting HIV-1 capsid inhibitor administered only twice yearly. With its disruptive mechanism of action, exceptional clinical efficacy, and extremely low dosing frequency, it is comprehensively reshaping the market landscape for HIV/AIDS treatment and prevention. Its core advantage lies in fundamentally resolving the long-standing challenge of patient adherence associated with traditional daily oral regimens, while also demonstrating potent inhibitory activity against multidrug-resistant viral strains. It serves both as a vital salvage therapy for advanced patients with treatment failure and opens up a highly effective and convenient new avenue for pre-exposure prophylaxis (PrEP) in at-risk populations. Against the backdrop of sustained strong global demand for HIV prevention and treatment, the drug has rapidly secured a strong market position through its differentiated product strengths, competing directly with similar products especially in the long-acting prevention sector and leading the industry’s paradigm shift from daily medication to long-acting injection. However, its market expansion faces significant challenges: the prohibitively high pricing of the originator drug severely limits accessibility in middle- and high-income countries. Although generic drug promotion via patent licensing in low- and middle-income countries has expanded coverage, price stratification, regional access disparities, and supply chain development remain core constraints to its global penetration. Overall, with its breakthrough clinical value and innovative positioning, lenacapavir has emerged as a high-growth blockbuster product in the HIV field, and its future market performance will be highly dependent on pricing strategies, insurance coverage, and collaborative advancement of global public health resources.

This report delivers a comprehensive overview of the global Lenacapavir market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lenacapavir. The Lenacapavir market size, estimates, and forecasts are provided in terms of sales volume (Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Lenacapavir market comprehensively. Regional market sizes by Type, by Application, by Dosage Form, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Lenacapavir manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Lenacapavir Market Report

Chapter Outline

1.1 Product Definition

1.2 Lenacapavir by Type

1.2.1 Global Lenacapavir Market Value by Type: 2025 vs 2032

1.2.2 0.3 g

1.2.3 1.5 mL

1.3 Lenacapavir by Dosage Form

1.3.1 Global Lenacapavir Market Value by Dosage Form: 2025 vs 2032

1.3.2 Tablets

1.3.3 Injection

1.4 Lenacapavir by Route of Administration

1.4.1 Global Lenacapavir Market Value by Route of Administration: 2025 vs 2032

1.4.2 Oral Administration

1.4.3 Subcutaneous Injection

1.5 Lenacapavir by Sales Channels

1.5.1 Global Lenacapavir Market Value by Sales Channels: 2025 vs 2032

1.5.2 Hospital

1.5.3 Retail

1.5.4 Online

1.6 Lenacapavir by Application

1.6.1 Global Lenacapavir Market Value by Application: 2025 vs 2032

1.6.2 Multidrug-Resistant HIV-1 Infection

1.6.3 Treatment Of HIV Infection In Adults

1.6.4 Others

1.7 Global Lenacapavir Market Size Estimates and Forecasts

1.7.1 Global Lenacapavir Revenue 2021–2032

1.7.2 Global Lenacapavir Sales 2021–2032

1.7.3 Global Lenacapavir Market Average Price (2021–2032)

1.8 Assumptions and Limitations

2.1 Global Lenacapavir Sales Market Share by Manufacturers (2021–2026)

2.2 Global Lenacapavir Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Lenacapavir Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Lenacapavir, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Lenacapavir, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Lenacapavir, Product Types and Applications

2.7 Global Key Manufacturers of Lenacapavir, Date of Entry into the Industry

2.8 Global Lenacapavir Market Competitive Situation and Trends

2.8.1 Global Lenacapavir Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Lenacapavir Players Market Share by Revenue

2.8.3 Global Lenacapavir Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Lenacapavir Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Lenacapavir Sales by Region: 2021–2032

3.2.1 Global Lenacapavir Sales by Region: 2021–2026

3.2.2 Global Lenacapavir Sales by Region: 2027–2032

3.3 Global Lenacapavir Revenue by Region: 2021–2032

3.3.1 Global Lenacapavir Revenue by Region: 2021–2026

3.3.2 Global Lenacapavir Revenue by Region: 2027–2032

3.4 North America Lenacapavir Market Facts & Figures by Country

3.4.1 North America Lenacapavir Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Lenacapavir Sales by Country (2021–2032)

3.4.3 North America Lenacapavir Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Lenacapavir Market Facts & Figures by Country

3.5.1 Europe Lenacapavir Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Lenacapavir Sales by Country (2021–2032)

3.5.3 Europe Lenacapavir Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Lenacapavir Market Facts & Figures by Region

3.6.1 Asia Pacific Lenacapavir Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Lenacapavir Sales by Region (2021–2032)

3.6.3 Asia Pacific Lenacapavir Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Lenacapavir Market Facts & Figures by Country

3.7.1 Latin America Lenacapavir Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Lenacapavir Sales by Country (2021–2032)

3.7.3 Latin America Lenacapavir Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Lenacapavir Market Facts & Figures by Country

3.8.1 Middle East and Africa Lenacapavir Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Lenacapavir Sales by Country (2021–2032)

3.8.3 Middle East and Africa Lenacapavir Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Lenacapavir Sales by Type (2021–2032)

4.1.1 Global Lenacapavir Sales by Type (2021–2026)

4.1.2 Global Lenacapavir Sales by Type (2027–2032)

4.1.3 Global Lenacapavir Sales Market Share by Type (2021–2032)

4.2 Global Lenacapavir Revenue by Type (2021–2032)

4.2.1 Global Lenacapavir Revenue by Type (2021–2026)

4.2.2 Global Lenacapavir Revenue by Type (2027–2032)

4.2.3 Global Lenacapavir Revenue Market Share by Type (2021–2032)

4.3 Global Lenacapavir Price by Type (2021–2032)

5.1 Global Lenacapavir Sales by Application (2021–2032)

5.1.1 Global Lenacapavir Sales by Application (2021–2026)

5.1.2 Global Lenacapavir Sales by Application (2027–2032)

5.1.3 Global Lenacapavir Sales Market Share by Application (2021–2032)

5.2 Global Lenacapavir Revenue by Application (2021–2032)

5.2.1 Global Lenacapavir Revenue by Application (2021–2026)

5.2.2 Global Lenacapavir Revenue by Application (2027–2032)

5.2.3 Global Lenacapavir Revenue Market Share by Application (2021–2032)

5.3 Global Lenacapavir Price by Application (2021–2032)

6.1 Gilead Sciences

6.1.1 Gilead Sciences Company Information

6.1.2 Gilead Sciences Description and Business Overview

6.1.3 Gilead Sciences Lenacapavir Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Gilead Sciences Lenacapavir Product Portfolio

6.1.5 Gilead Sciences Recent Developments/Updates

6.2 WuXi AppTec

6.2.1 WuXi AppTec Company Information

6.2.2 WuXi AppTec Description and Business Overview

6.2.3 WuXi AppTec Lenacapavir Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 WuXi AppTec Lenacapavir Product Portfolio

6.2.5 WuXi AppTec Recent Developments/Updates

7.1 Lenacapavir Industry Chain Analysis

7.2 Lenacapavir Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Lenacapavir Production Mode & Process Analysis

7.4 Lenacapavir Sales and Marketing

7.4.1 Lenacapavir Sales Channels

7.4.2 Lenacapavir Distributors

7.5 Lenacapavir Customer Analysis

8.1 Lenacapavir Industry Trends

8.2 Lenacapavir Market Drivers

8.3 Lenacapavir Market Challenges

8.4 Lenacapavir Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global Lenacapavir Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global Lenacapavir Market Value by Dosage Form (US$ Million), 2025 vs 2032

 Table 3. Global Lenacapavir Market Value by Route of Administration (US$ Million), 2025 vs 2032

 Table 4. Global Lenacapavir Market Value by Sales Channels (US$ Million), 2025 vs 2032

 Table 5. Global Lenacapavir Market Value by Application (US$ Million), 2025 vs 2032

 Table 6. Global Lenacapavir Market Competitive Situation by Manufacturers in 2025

 Table 7. Global Lenacapavir Sales (Units) of Key Manufacturers (2021–2026)

 Table 8. Global Lenacapavir Sales Market Share by Manufacturers (2021–2026)

 Table 9. Global Lenacapavir Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 10. Global Lenacapavir Revenue Share by Manufacturers (2021–2026)

 Table 11. Global Market Lenacapavir Average Price (US$/Unit) of Key Manufacturers (2021–2026)

 Table 12. Global Key Players of Lenacapavir, Industry Ranking, 2023 vs 2024 vs 2025

 Table 13. Global Key Manufacturers of Lenacapavir, Manufacturing Sites and Headquarters

 Table 14. Global Key Manufacturers of Lenacapavir, Product Types and Applications

 Table 15. Global Key Manufacturers of Lenacapavir, Date of Entry into the Industry

 Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 17. Global Lenacapavir Companies by Tier (Tier 1, Tier 2, Tier 3), based on Lenacapavir Revenue, 2025

 Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 19. Global Lenacapavir Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 20. Global Lenacapavir Sales by Region (Units), 2021–2026

 Table 21. Global Lenacapavir Sales Market Share by Region (2021–2026)

 Table 22. Global Lenacapavir Sales by Region (Units), 2027–2032

 Table 23. Global Lenacapavir Sales Market Share by Region (2027–2032)

 Table 24. Global Lenacapavir Revenue by Region (US$ Million), 2021–2026

 Table 25. Global Lenacapavir Revenue Market Share by Region (2021–2026)

 Table 26. Global Lenacapavir Revenue by Region (US$ Million), 2027–2032

 Table 27. Global Lenacapavir Revenue Market Share by Region (2027–2032)

 Table 28. North America Lenacapavir Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 29. North America Lenacapavir Sales by Country (Units), 2021–2026

 Table 30. North America Lenacapavir Sales by Country (Units), 2027–2032

 Table 31. North America Lenacapavir Revenue by Country (US$ Million), 2021–2026

 Table 32. North America Lenacapavir Revenue by Country (US$ Million), 2027–2032

 Table 33. Europe Lenacapavir Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 34. Europe Lenacapavir Sales by Country (Units), 2021–2026

 Table 35. Europe Lenacapavir Sales by Country (Units), 2027–2032

 Table 36. Europe Lenacapavir Revenue by Country (US$ Million), 2021–2026

 Table 37. Europe Lenacapavir Revenue by Country (US$ Million), 2027–2032

 Table 38. Asia Pacific Lenacapavir Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 39. Asia Pacific Lenacapavir Sales by Region (Units), 2021–2026

 Table 40. Asia Pacific Lenacapavir Sales by Region (Units), 2027–2032

 Table 41. Asia Pacific Lenacapavir Revenue by Region (US$ Million), 2021–2026

 Table 42. Asia Pacific Lenacapavir Revenue by Region (US$ Million), 2027–2032

 Table 43. Latin America Lenacapavir Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 44. Latin America Lenacapavir Sales by Country (Units), 2021–2026

 Table 45. Latin America Lenacapavir Sales by Country (Units), 2027–2032

 Table 46. Latin America Lenacapavir Revenue by Country (US$ Million), 2021–2026

 Table 47. Latin America Lenacapavir Revenue by Country (US$ Million), 2027–2032

 Table 48. Middle East and Africa Lenacapavir Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 49. Middle East and Africa Lenacapavir Sales by Country (Units), 2021–2026

 Table 50. Middle East and Africa Lenacapavir Sales by Country (Units), 2027–2032

 Table 51. Middle East and Africa Lenacapavir Revenue by Country (US$ Million), 2021–2026

 Table 52. Middle East and Africa Lenacapavir Revenue by Country (US$ Million), 2027–2032

 Table 53. Global Lenacapavir Sales (Units) by Type (2021–2026)

 Table 54. Global Lenacapavir Sales (Units) by Type (2027–2032)

 Table 55. Global Lenacapavir Sales Market Share by Type (2021–2026)

 Table 56. Global Lenacapavir Sales Market Share by Type (2027–2032)

 Table 57. Global Lenacapavir Revenue (US$ Million) by Type (2021–2026)

 Table 58. Global Lenacapavir Revenue (US$ Million) by Type (2027–2032)

 Table 59. Global Lenacapavir Revenue Market Share by Type (2021–2026)

 Table 60. Global Lenacapavir Revenue Market Share by Type (2027–2032)

 Table 61. Global Lenacapavir Price (US$/Unit) by Type (2021–2026)

 Table 62. Global Lenacapavir Price (US$/Unit) by Type (2027–2032)

 Table 63. Global Lenacapavir Sales (Units) by Application (2021–2026)

 Table 64. Global Lenacapavir Sales (Units) by Application (2027–2032)

 Table 65. Global Lenacapavir Sales Market Share by Application (2021–2026)

 Table 66. Global Lenacapavir Sales Market Share by Application (2027–2032)

 Table 67. Global Lenacapavir Revenue (US$ Million) by Application (2021–2026)

 Table 68. Global Lenacapavir Revenue (US$ Million) by Application (2027–2032)

 Table 69. Global Lenacapavir Revenue Market Share by Application (2021–2026)

 Table 70. Global Lenacapavir Revenue Market Share by Application (2027–2032)

 Table 71. Global Lenacapavir Price (US$/Unit) by Application (2021–2026)

 Table 72. Global Lenacapavir Price (US$/Unit) by Application (2027–2032)

 Table 73. Gilead Sciences Company Information

 Table 74. Gilead Sciences Description and Business Overview

 Table 75. Gilead Sciences Lenacapavir Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 76. Gilead Sciences Lenacapavir Product

 Table 77. Gilead Sciences Recent Developments/Updates

 Table 78. WuXi AppTec Company Information

 Table 79. WuXi AppTec Description and Business Overview

 Table 80. WuXi AppTec Lenacapavir Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 81. WuXi AppTec Lenacapavir Product

 Table 82. WuXi AppTec Recent Developments/Updates

 Table 83. Key Raw Materials Lists

 Table 84. Raw Materials Key Suppliers Lists

 Table 85. Lenacapavir Distributors List

 Table 86. Lenacapavir Customers List

 Table 87. Lenacapavir Market Trends

 Table 88. Lenacapavir Market Drivers

 Table 89. Lenacapavir Market Challenges

 Table 90. Lenacapavir Market Restraints

 Table 91. Research Programs/Design for This Report

 Table 92. Key Data Information from Secondary Sources

 Table 93. Key Data Information from Primary Sources

 Table 94. Authors List of This Report

List of Figures

 Figure 1. Product Picture of Lenacapavir

 Figure 2. Global Lenacapavir Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global Lenacapavir Market Share by Type: 2025 & 2032

 Figure 4. 0.3 g Product Picture

 Figure 5. 1.5 mL Product Picture

 Figure 6. Global Lenacapavir Market Value by Dosage Form (US$ Million), 2021–2032

 Figure 7. Global Lenacapavir Market Share by Dosage Form: 2025 vs 2032

 Figure 8. Tablets Product Picture

 Figure 9. Injection Product Picture

 Figure 10. Global Lenacapavir Market Value by Route of Administration (US$ Million), 2021–2032

 Figure 11. Global Lenacapavir Market Share by Route of Administration: 2025 vs 2032

 Figure 12. Oral Administration Product Picture

 Figure 13. Subcutaneous Injection Product Picture

 Figure 14. Global Lenacapavir Market Value by Sales Channels (US$ Million), 2021–2032

 Figure 15. Global Lenacapavir Market Share by Sales Channels: 2025 vs 2032

 Figure 16. Hospital Product Picture

 Figure 17. Retail Product Picture

 Figure 18. Online Product Picture

 Figure 19. Global Lenacapavir Market Value by Application (US$ Million), 2021–2032

 Figure 20. Global Lenacapavir Market Share by Application: 2025 & 2032

 Figure 21. Multidrug-Resistant HIV-1 Infection

 Figure 22. Treatment Of HIV Infection In Adults

 Figure 23. Others

 Figure 24. Global Lenacapavir Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 25. Global Lenacapavir Market Size (US$ Million), 2021–2032

 Figure 26. Global Lenacapavir Sales (Units), 2021–2032

 Figure 27. Global Lenacapavir Average Price (US$/Unit), 2021–2032

 Figure 28. Lenacapavir Report Years Considered

 Figure 29. Lenacapavir Sales Share by Manufacturers in 2025

 Figure 30. Global Lenacapavir Revenue Share by Manufacturers in 2025

 Figure 31. Top 5 and Top 10 Global Lenacapavir Players: Market Share by Revenue in Lenacapavir in 2025

 Figure 32. Lenacapavir Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 33. Global Lenacapavir Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 34. North America Lenacapavir Sales Market Share by Country (2021–2032)

 Figure 35. North America Lenacapavir Revenue Market Share by Country (2021–2032)

 Figure 36. United States Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 37. Canada Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. Europe Lenacapavir Sales Market Share by Country (2021–2032)

 Figure 39. Europe Lenacapavir Revenue Market Share by Country (2021–2032)

 Figure 40. Germany Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. France Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. U.K. Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 43. Italy Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 44. Russia Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 45. Asia Pacific Lenacapavir Sales Market Share by Region (2021–2032)

 Figure 46. Asia Pacific Lenacapavir Revenue Market Share by Region (2021–2032)

 Figure 47. China Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 48. Japan Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 49. South Korea Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 50. India Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 51. Australia Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 52. China Taiwan Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 53. Southeast Asia Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 54. Latin America Lenacapavir Sales Market Share by Country (2021–2032)

 Figure 55. Latin America Lenacapavir Revenue Market Share by Country (2021–2032)

 Figure 56. Mexico Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 57. Brazil Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 58. Argentina Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 59. Colombia Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 60. Middle East and Africa Lenacapavir Sales Market Share by Country (2021–2032)

 Figure 61. Middle East and Africa Lenacapavir Revenue Market Share by Country (2021–2032)

 Figure 62. Turkey Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 63. Saudi Arabia Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 64. UAE Lenacapavir Revenue Growth Rate (US$ Million), 2021–2032

 Figure 65. Global Sales Market Share of Lenacapavir by Type (2021–2032)

 Figure 66. Global Revenue Market Share of Lenacapavir by Type (2021–2032)

 Figure 67. Global Lenacapavir Price (US$/Unit) by Type (2021–2032)

 Figure 68. Global Sales Market Share of Lenacapavir by Application (2021–2032)

 Figure 69. Global Revenue Market Share of Lenacapavir by Application (2021–2032)

 Figure 70. Global Lenacapavir Price (US$/Unit) by Application (2021–2032)

 Figure 71. Lenacapavir Value Chain

 Figure 72. Channels of Distribution (Direct Vs Distribution)

 Figure 73. Bottom-up and Top-down Approaches for This Report

 Figure 74. Data Triangulation

 Figure 75. Key Executives Interviewed